DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella

Information source: HRA Pharma
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Emergency Contraception

Intervention: ella (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: HRA Pharma

Official(s) and/or principal investigator(s):
Paul Fine, MD, Principal Investigator, Affiliation: Planned Parenthood Gulf Coast

Overall contact:
Paul Fine, MD, Phone: +17138316553, Email: Paul.Fine@ppgulfcoast.org


The study is aimed at assessing the clinical follow-up and the outcomes of pregnancies exposed to ella, whether due to failure of the emergency contraception or inadvertent exposure during pregnancy.

Clinical Details

Official title: Prospective Multicenter Observational Study to Assess Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella

Study design: Time Perspective: Prospective

Primary outcome: pregnancy outcome


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Female.


- Pregnant women, exposed to ella during the menstrual cycle in which the pregnancy

started (treatment failure) or at any time during pregnancy (inadvertent exposure during pregnancy)

- Adolescents and/or adults in the USA, depending on the respective State law

Locations and Contacts

Paul Fine, MD, Phone: +17138316553, Email: Paul.Fine@ppgulfcoast.org

Planned Parenthood Federation of America, Inc, New York,, New York 10001, United States; Recruiting
Additional Information

Starting date: January 2012
Last updated: September 18, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017